{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:01:51Z","timestamp":1785841311010,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Children with rheumatic diseases (cRD) receiving immunosuppressive medications (IM) are at a higher risk for acquiring potentially lethal pathogens, including<jats:italic>Histoplasma capsulatum<\/jats:italic>(histoplasmosis), a fungal infection that can lead to prolonged hospitalization, organ damage, and death. Withholding IM during serious infections is recommended yet poses risk of rheumatic disease flares. Conversely, reinitiating IM increases risk for infection recurrence. Tumor necrosis factor alpha inhibitor (TNFai) biologic therapy carries the highest risk for histoplasmosis infection after epidemiological exposure, so other IM are preferred during active histoplasmosis infection. There is limited guidance as to when and how IM can be reinitiated in cRD with histoplasmosis. This case series chronicles resumption of IM, including non-TNFai biologics, disease-modifying anti-rheumatic drugs (DMARDs), and corticosteroids, following histoplasmosis among cRD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We examine clinical characteristics and outcomes of 9 patients with disseminated or pulmonary histoplasmosis and underlying rheumatic disease [juvenile idiopathic arthritis (JIA), childhood-onset systemic lupus erythematosus (cSLE), and mixed connective tissue disease (MCTD)] after reintroduction of IM. All DMARDs and biologics were halted at histoplasmosis diagnosis, except hydroxychloroquine (HCQ), and patients began antifungals. Following IM discontinuation, all patients required systemic or intra-articular steroids during histoplasmosis treatment, with 4\/9 showing Cushingoid features. Four patients began new IM regimens [2 abatacept (ABA), 1 HCQ, and 1 methotrexate (MTX)] while still positive for histoplasmosis, with 3\/4 (ABA, MTX, HCQ) later clearing their histoplasmosis and 1 (ABA) showing decreasing antigenemia. Collectively, 8\/9 patients initiated or continued DMARDs and\/or non-TNFai biologic use (5 ABA, 1 tocilizumab, 1 ustekinumab, 3 MTX, 4 HCQ, 1 leflunomide). No fatalities, exacerbations, or recurrences of histoplasmosis occurred during follow-up (median 33 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In our cohort of cRD, histoplasmosis course following reintroduction of non-TNFai IM was favorable, but additional studies are needed to evaluate optimal IM management during acute histoplasmosis and recovery. In this case series, non-TNFai biologic, DMARD, and steroid treatments did not appear to cause histoplasmosis recurrence. Adverse events from corticosteroid use were common. Further research is needed to implement guidelines for optimal use of non-TNFai (like ABA), DMARDs, and corticosteroids in cRD following histoplasmosis presentation.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12969-021-00581-7","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T12:09:51Z","timestamp":1623067791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series"],"prefix":"10.1186","volume":"19","author":[{"given":"Rachel A.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Barbar-Smiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagri","family":"Yildirim-Toruner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica I.","family":"Ardura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy P.","family":"Ardoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoghik","family":"Akoghlanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"4","key":"581_CR1","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.pcl.2018.04.008","volume":"65","author":"GC Higgins","year":"2018","unstructured":"Higgins GC. Complications of Treatments for Pediatric Rheumatic Diseases. Pediatr Clin North Am. 2018;65(4):827\u201354.","journal-title":"Pediatr Clin North Am"},{"issue":"11","key":"581_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/1756-185X.12822","volume":"19","author":"YH Lee","year":"2016","unstructured":"Lee YH, et al. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2016;19(11):1103\u201311.","journal-title":"Int J Rheum Dis"},{"key":"581_CR3","unstructured":"Gerriets V, et al. Tumor Necrosis Factor Inhibitors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [Updated 2020 Jul 4]."},{"issue":"6","key":"581_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1378\/chest.29.6.649","volume":"29","author":"NE Manos","year":"1956","unstructured":"Manos NE, et al. Geographic variation in the prevalence of histoplasmin sensitivity. Dis Chest. 1956;29(6):649\u201368.","journal-title":"Dis Chest"},{"issue":"1","key":"581_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/clinids\/23.1.146","volume":"23","author":"A Zumla","year":"1996","unstructured":"Zumla A, et al. Granulomatous infections: etiology and classification. Clin Infect Dis. 1996;23(1):146\u201358.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"581_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2165\/00003495-200969110-00002","volume":"69","author":"JA Smith","year":"2009","unstructured":"Smith JA, et al. Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-a Inhibitor Therapy. Drugs. 2009;69(11):1403\u201315.","journal-title":"Drugs"},{"issue":"5","key":"581_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1055\/s-0035-1562899","volume":"36","author":"CA Hage","year":"2015","unstructured":"Hage CA, et al. Histoplasmosis: Up-to-Date Evidence-Based Approach to Diagnosis and Management. Semin Respir Crit Care Med. 2015;36(5):729\u201345.","journal-title":"Semin Respir Crit Care Med"},{"issue":"7","key":"581_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/521259","volume":"45","author":"LJ Wheat","year":"2007","unstructured":"Wheat LJ, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807\u201325.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"581_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1569-1993(03)00022-5","volume":"2","author":"E De Wachter","year":"2003","unstructured":"De Wachter E, et al. Inhaled budesonide induced Cushing\u2019s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros. 2003;2(2):72\u20135.","journal-title":"J Cyst Fibros"},{"issue":"8","key":"581_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/thorax.57.8.749","volume":"57","author":"JS Parmar","year":"2002","unstructured":"Parmar JS, et al. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax. 2002;57(8):749\u201350.","journal-title":"Thorax"},{"issue":"1","key":"581_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1600-0773.1999.tb01059.x","volume":"85","author":"T Varis","year":"1999","unstructured":"Varis T, et al. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol. 1999;85(1):29\u201332.","journal-title":"Pharmacol Toxicol"},{"issue":"5","key":"581_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","volume":"51","author":"B Lebrun-Vignes","year":"2001","unstructured":"Lebrun-Vignes B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol. 2001;51(5):443\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"581_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1183\/09031936.02.00248002","volume":"20","author":"M Skov","year":"2002","unstructured":"Skov M, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J. 2002;20(1):127\u201333.","journal-title":"Eur Respir J"},{"issue":"225","key":"581_CR14","doi-asserted-by":"crossref","first-page":"pe13","DOI":"10.1126\/stke.2252004pe13","volume":"2004","author":"MR Philips","year":"2004","unstructured":"Philips MR. Methotrexate and Ras methylation: a new trick for an old drug? Sci STKE. 2004;2004(225):pe13.","journal-title":"Sci STKE"},{"issue":"4","key":"581_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jcf.2012.10.007","volume":"12","author":"FJ Gilchrist","year":"2013","unstructured":"Gilchrist FJ, et al. Itraconazole and inhaled fluticasone causing hypothalamic\u2013pituitary\u2013adrenal axis suppression in adults with cystic fibrosis. J Cyst Fibros. 2013;12(4):399\u2013402.","journal-title":"J Cyst Fibros"},{"issue":"6","key":"581_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, et al. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020;172(6):369\u201380.","journal-title":"Ann Intern Med"},{"key":"581_CR17","doi-asserted-by":"crossref","unstructured":"Tsiodras S, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181 \u2013 94.","DOI":"10.4065\/83.2.181"},{"issue":"1","key":"581_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12876-020-01290-3","volume":"20","author":"S Park","year":"2020","unstructured":"Park S, et al. Cholestasis and disseminated histoplasmosis in a psoriatic patient on infliximab: case report and review of literature. BMC Gastroenterol. 2020;20(1):141.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"581_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ibd.21378","volume":"17","author":"JL Dotson","year":"2011","unstructured":"Dotson JL, et al. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis. 2011;17(1):56\u201361.","journal-title":"Inflamm Bowel Dis"},{"key":"581_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1086\/648724","volume":"50","author":"CA Hage","year":"2010","unstructured":"Hage CA, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50:85\u201392.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"581_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40588-016-0034-6","volume":"3","author":"IS Schwartz","year":"2016","unstructured":"Schwartz IS, et al. Endemic Mycoses: What\u2019s New About Old Diseases? Curr Clin Microbiol Rep. 2016;3(2):71\u201380.","journal-title":"Curr Clin Microbiol Rep"},{"key":"581_CR22","doi-asserted-by":"crossref","unstructured":"Vergidis P, et al. Histoplasmosis complicating tumor necrosis factor-\u03b1 blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015 Aug 1;61(3):409 \u2013 17.","DOI":"10.1093\/cid\/civ299"},{"key":"581_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1471-2334-11-145","volume":"11","author":"TC Olson","year":"2011","unstructured":"Olson TC, et al. Histoplasmosis infection in patients with rheumatoid arthritis, 1998\u20132009. BMC Infect Dis. 2011;11:145.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 2","key":"581_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"JW Baddley","year":"2018","unstructured":"Baddley JW, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). Clin Microbiol Infect. 2018;24(Suppl 2):10\u201320.","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"581_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):21\u201340.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"581_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-019-1921-z","volume":"21","author":"G Ozen","year":"2019","unstructured":"Ozen G, et al. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Arthritis Res Ther. 2019;21(1):141.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"581_CR27","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"581_CR28","first-page":"OR01","volume":"11","author":"W Sukhumthammarat","year":"2017","unstructured":"Sukhumthammarat W, et al. Local Injection of Triamcinolone Acetonide: A Forgotten Aetiology of Cushing\u2019s Syndrome. J Clin Diagn Res. 2017;11(6):OR01\u20132.","journal-title":"J Clin Diagn Res"},{"key":"581_CR29","doi-asserted-by":"crossref","unstructured":"Alkhuder L, et al. Infantile Iatrogenic Cushing Syndrome due to Topical Steroids. Case Reports in Pediatrics, vol. 2019, 4 pages. Article ID 2652961.","DOI":"10.1155\/2019\/2652961"},{"issue":"3","key":"581_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0213-005X(04)73056-6","volume":"22","author":"D Pietrobon","year":"2004","unstructured":"Pietrobon D, et al. Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enferm Infecc Microbiol Clin. 2004;22(3):156\u20139.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"4","key":"581_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/00005792-198407000-00002","volume":"63","author":"LJ Wheat","year":"1984","unstructured":"Wheat LJ, et al. Cavitary histoplasmosis occurring during two large urban outbreaks. Analysis of clinical, epidemiologic, roentgenographic, and laboratory features. Medicine. 1984;63(4):201\u20139.","journal-title":"Medicine"},{"issue":"8","key":"581_CR32","first-page":"785","volume":"49","author":"AL Colombo","year":"2011","unstructured":"Colombo AL, et al. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol. 2011;49(8):785\u201398.","journal-title":"Med Mycol"},{"issue":"6","key":"581_CR33","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1086\/500405","volume":"42","author":"JH Chu","year":"2006","unstructured":"Chu JH, et al. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis. 2006;42(6):822\u20135.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"581_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/jpids\/piy073","volume":"8","author":"CP Ouellette","year":"2019","unstructured":"Ouellette CP, et al. Pediatric Histoplasmosis in an Area of Endemicity: A Contemporary Analysis. J Pediatric Infect Dis Soc. 2019;8(5):400\u20137.","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00581-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T04:58:58Z","timestamp":1672376338000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00581-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00581-7","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An Institutional Review Board was obtained from Nationwide Children\u2019s Hospital IRB17-01241.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}